Published in Br J Cancer on January 13, 2003
Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer (2005) 1.52
Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. Br J Cancer (2006) 1.29
Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer (2011) 1.26
Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer (2005) 1.17
Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res (2009) 1.08
Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br J Cancer (2005) 1.05
Nuclear survivin as a biomarker for non-small-cell lung cancer. Br J Cancer (2004) 1.03
Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical significance. Clin Exp Metastasis (2009) 0.97
Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol (2007) 0.95
Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis. PLoS One (2012) 0.95
Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol (2007) 0.92
The RNA-binding protein CUG-BP1 increases survivin expression in oesophageal cancer cells through enhanced mRNA stability. Biochem J (2012) 0.90
Survivin delta Ex3 overexpression in thyroid malignancies. PLoS One (2014) 0.89
Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer (2008) 0.87
Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol (2010) 0.87
Survivin: A molecular biomarker in cancer. Indian J Med Res (2015) 0.86
Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch (2012) 0.86
Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res (2011) 0.85
Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci (2007) 0.85
Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol (2008) 0.85
Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett (2008) 0.84
Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys (2008) 0.83
Pro-oncogene Pokemon promotes breast cancer progression by upregulating survivin expression. Breast Cancer Res (2011) 0.83
Targeting Cell Survival Proteins for Cancer Cell Death. Pharmaceuticals (Basel) (2016) 0.81
Ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in oesophageal cancer cells: involvement of the p38MAPK signalling pathway. Br J Cancer (2003) 0.81
Survivin -31G>C polymorphism and gastrointestinal tract cancer risk: a meta-analysis. PLoS One (2013) 0.78
Significance of intracellular localization of survivin in cervical squamous cell lesions: Correlation with disease progression. Oncol Lett (2014) 0.76
Clinical correlation of nuclear survivin in esophageal squamous cell carcinoma. Med Oncol (2012) 0.76
Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas. PLoS One (2016) 0.75
Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level. Oncol Lett (2017) 0.75
Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cell Mol Biol Lett (2017) 0.75
Apoptosis in the pathogenesis and treatment of disease. Science (1995) 20.24
Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev (1995) 13.66
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med (1997) 12.65
IAP family proteins--suppressors of apoptosis. Genes Dev (1999) 9.96
Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 8.60
Analysis of human transcriptomes. Nat Genet (1999) 6.14
Cell death in development. Cell (1999) 6.01
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res (1998) 5.41
Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood (1996) 5.13
Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res (1998) 3.63
Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res (2000) 3.24
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology (2000) 2.15
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer (2001) 2.10
Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet (1998) 2.08
Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest (1999) 2.00
The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res (2000) 1.81
Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett (2001) 1.56
Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol (2001) 1.51
CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res (2002) 1.44
Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol (2001) 1.08
Expression of the apoptosis inhibitor survivin in aggressive squamous cell carcinoma. Exp Mol Pathol (2001) 0.93
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem (1984) 18.48
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol (1984) 17.76
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer (1983) 11.19
Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med (1995) 4.51
Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood (1997) 4.36
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J Histochem Cytochem (1980) 3.47
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell (1992) 3.21
The normal and malignant germinal centre. Clin Haematol (1982) 3.19
A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood (2000) 3.13
Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol (2002) 3.05
Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood (1989) 2.95
Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A (1991) 2.82
Ribonuclease H. An enzyme degrading the RNA moiety of DNA-RNA hybrids. Eur J Biochem (1970) 2.81
Monoclonal antibodies OKT 11 and OKT 11A have pan-T reactivity and block sheep erythrocyte "receptors". Eur J Immunol (1982) 2.72
Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Pathol (1982) 2.69
CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood (1995) 2.67
Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology (1998) 2.60
Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med (1997) 2.59
Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer (1982) 2.51
Immunohistological analysis of human mononuclear phagocytes and dendritic cells by using monoclonal antibodies. Lab Invest (1986) 2.42
Enzyme from calf thymus degrading the RNA moiety of DNA-RNA Hybrids: effect on DNA-dependent RNA polymerase. Science (1969) 2.41
Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am J Pathol (1992) 2.37
Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol (1985) 2.35
In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. Hepatology (1989) 2.34
Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet (1985) 2.25
Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet (1984) 2.25
The monoclonal antibodies alpha S-HCL 1 (alpha Leu-14) and alpha S-HCL 3 (alpha Leu-M5) allow the diagnosis of hairy cell leukemia. Blood (1985) 2.24
Different beta-subunits determine G-protein interaction with transmembrane receptors. Nature (1992) 2.23
Use of freeze-dried paraffin-embedded sections for immunohistologic staining with monoclonal antibodies. Lab Invest (1985) 2.23
Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res (1984) 2.03
Differential expression of homing-associated adhesion molecules by T cell subsets in man. J Immunol (1990) 2.01
Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol (1986) 1.97
Production of a monoclonal antibody reactive with human dendritic reticulum cells and its use in the immunohistological analysis of lymphoid tissue. J Clin Pathol (1983) 1.85
Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma. Gut (1993) 1.83
Human complement (C3b) receptors defined by a mouse monoclonal antibody. Immunology (1982) 1.78
Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. Gastroenterology (1990) 1.77
The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J Pathol (2000) 1.76
BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood (1989) 1.76
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Expression of Epstein-Barr virus-gene products in Burkitt's lymphoma in Northeast Brazil. Blood (1996) 1.74
Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science (1993) 1.71
Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer (1982) 1.67
T-cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. Ophthalmology (1999) 1.66
European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL) Ann Oncol (1994) 1.65
A randomized controlled trial of the impact of therapeutic horse riding on the quality of life, health, and function of children with cerebral palsy. Dev Med Child Neurol (2009) 1.63
Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma. Int J Cancer (1985) 1.62
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J Clin Pathol (1990) 1.60
Human dendritic reticulum cells of lymphoid follicles: their antigenic profile and their identification as multinucleated giant cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1983) 1.58
Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am J Pathol (2000) 1.57
Epstein-Barr virus/complement receptor and epithelial cells. Lancet (1989) 1.56
An immunohistological study of the cellular constituents of Hodgkin's disease using a monoclonal antibody panel. Histopathology (1984) 1.55
Colonic strictures following nonoperative management of necrotizing enterocolitis. J Pediatr Surg (1975) 1.55
Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol (1991) 1.55
High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol (1990) 1.54
Monokine expression in Langerhans' cell histiocytosis and sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) J Pathol (1996) 1.53
Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood (1999) 1.53
Identification of Epstein-Barr virus-infected cells in tonsils of acute infectious mononucleosis by in situ hybridization. Hum Pathol (1989) 1.52
Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol (2002) 1.51
Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol (1981) 1.50
New approach to assessing lung tumours in man. J Clin Pathol (1986) 1.50
Acquired resistance to Listeria monocytogenes is mediated by Lyt-2+ T cells independently of the influx of monocytes into granulomatous lesions. J Exp Med (1989) 1.50
Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer (2012) 1.48
Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie (2004) 1.48
CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A (1991) 1.47
Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol Oncol (1984) 1.47
Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood (1992) 1.45
The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. J Immunol (1990) 1.44
Towards a better definition of human leucocyte surface molecules. Immunol Today (1989) 1.42
Low-grade non-Hodgkin's lymphoma after high-grade non-Hodgkin's lymphoma in a child with ataxia telangiectasia. Cancer (1994) 1.40
Virostatic therapy for advanced lymphoproliferation associated with the Epstein-Barr virus in an HIV-infected patient. N Engl J Med (2000) 1.39
Phase-inversion sonography during the liver-specific late phase of contrast enhancement: improved detection of liver metastases. AJR Am J Roentgenol (2001) 1.38
Neurological deficit in a consecutive series of vertebral fracture patients with bony fragments within spinal canal. Spinal Cord (1997) 1.38
Risk factors for infection in fracture war wounds (1973 and 1982 wars, Israel) Mil Med (1991) 1.38
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report. Arthritis Rheum (1998) 1.37
The HML-1 antigen of intestinal lymphocytes is an activation antigen. J Immunol (1990) 1.36
Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia (2007) 1.36
Immunohistology and aetiology of histiocytic necrotizing lymphadenitis. Report of three instructive cases. Histopathology (1983) 1.35
Monoclonal antibodies in the diagnosis of Hodgkin's disease. The search for a rational panel. Am J Surg Pathol (1988) 1.35
Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood (1996) 1.34
Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. Lancet (1987) 1.34
Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol (1997) 1.34
The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen. Eur J Immunol (1994) 1.32
Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma: dissociation between phenotype and genotype. Leuk Res (1989) 1.31
Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review. Ups J Med Sci Suppl (1980) 1.31
Mutation of the cyclin-dependent kinase phosphorylation site in simian virus 40 (SV40) large T antigen specifically blocks SV40 origin DNA unwinding. J Virol (1993) 1.30
Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol (1991) 1.30
Adjustment problems in juvenile diabetes. Psychosom Med (1968) 1.30
The value of immunohistological screening in the production of monoclonal antibodies. J Immunol Methods (1982) 1.29
High serum level of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. AIDS (1994) 1.29
Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology (2006) 1.28